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Table S1. Segregation analysis in family 1 of three
microsatellite markers flanking KRT1 and the
pathogenic mutation p.Phe191Ile demonstrating
germline mosaicism.
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TO THE EDITOR
Erythropoietic protoporphyrin (EPP;
OMIM 177000) is an inherited porphyr-
in metabolism disorder caused by de-
creased activity of the ferrochelatase
(FECH; E.C. 4.99.1.1.), the final enzyme
in the heme biosynthetic pathway. This
pathway catalyzes the insertion of fer-
rous iron into protoporphyrin IX, forming
heme. Clinically, excess protoporphyrin
accumulates in the skin, causing painful
photosensitivity in patients, which be-
gins in early childhood. In fewer than
10% of patients, the accumulation of
protoporphyrin in the liver may lead to
hepatic injury (Todd, 1994).
EPP’s mode of inheritance is primar-
ily autosomal-dominant; however, the
disease has a low clinical penetrance,
with less than 10% of mutation carriers
developing overt clinical symptoms
(Schneider-Yin et al., 2000). The acti-
vity of FECH in EPP patients is often
only 10–30% of the normal level, that
is, less than 50% of that which would
be expected from an autosomal-domi-
nant inheritable disease (Todd, 1994).
Gouya et al. (1996) revealed that the
EPP phenotype in an affected family
resulted from the coinheritance of both
a low-expressing and a mutant allele.
The mechanism responsible for the low
expression of FECH was recently de-
monstrated to be an IVS348T/C poly-
morphism that modulates the use of a
constitutive aberrant acceptor splice
site 63 bp upstream of the normal site
(Gouya et al., 2002). The T to C
mutation at position IVS348 was
found to result in 40% aberrantly
spliced mRNA by a process called
nonsense-mediated mRNA decay. The
C allele was present in 11% of the
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Figure 1. Pedigrees of families 1 and 2 with EPP. We investigated two EPP probands and their relatives.
EPP diagnosis was based on typical skin symptoms and biochemical data, including an elevated
concentration of erythrocyte protoporphyrin. The proband from family 1 is photosensitive owing to
increased erythrocyte protoporphyrin, and also exhibits liver dysfunction. The symptomatic members of
family 2, including the proband, exhibit only photosensitivity. The solid symbols refer to symptomatic
individuals, and the probands are indicated by arrows. WT, wild-type. T and C represent wild-type
IVS348T and splice site modulator IVS348C, respectively. ND, not determined.
Abbreviations: EPP, erythropoietic protoporphyrin; FECH, ferrochelatase
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French controls. Furthermore, FECH
activity in lymphocytes was signifi-
cantly higher in individuals who were
homozygous for a T at the IVS348
position compared with those that were
heterozygous; individuals who were
homozygous for C showed the lowest
FECH activity. In the this study, we
investigated the inheritance of muta-
tions and the splice site modulator
IVS348C in the FECH gene in two
Japanese families with cases of EPP. In
addition, the frequency of the splice site
modulator IVS48C polymorphism in
Japanese population was examined.
Direct sequence analysis of the
entire coding region of the FECH gene
identified two novel mutations in two
Japanese families with histories of EPP
(Figure 1). The proband in family 1 was
heterozygous for a 3-bp deletion from
nucleotide positions 853 to 855 in exon
8, designated delCAA853. This nucleo-
tide deletion resulted in the deletion of
glutamine at amino-acid position 285.
Pedigree analysis of the other family
members by restriction digestion
analysis using BstXI revealed that the
mother and younger sisters, all asymp-
tomatic, were also heterozygous for this
mutation (Figure 1a). Screening of the
FECH gene in family 2 showed that the
proband was heterozygous for a C to T
substitution at nucleotide position 683
in exon 6, designated C683-T. This
transition resulted in a shift from a
proline to a leucine at amino-acid
position 228. Restriction digestion ana-
lysis with HaeIII of the other family
members demonstrated that the father
and younger brother were also hetero-
zygous for this mutation (Figure 1b).
These two mutations identified in the
this study were not detected in any of
the 208 control chromosomes, suggest-
ing that they are not common poly-
morphisms, but rather pathogenic
mutations.
To investigate the phenotypic effect
of the splice site modulator IVS348C
in Japanese EPP patients, restriction
fragment length polymorphism analyses
using Fnu4HI were performed. In fa-
mily 1, the proband is homozygous for
the IVS348C polymorphism, that is,
carrying a deleterious FECH mutation
in one allele and IVS348C in the
other, whereas asymptomatic carriers
have a wild-type T at position IVS348
in trans to the mutated allele (Figure
1a). These results suggest that in the
asymptomatic carriers in family 1,
normal expression of FECH from the
wild-type allele with IVS348T could
compensate for the putatively defective
enzymatic function of the protein ex-
pressed by the mutated allele (del-
CAA853), whereas in the proband, the
decreased FECH expression resulted
from the IVS348C polymorphism in
one allele and a deleterious mutation in
the other, thereby causing a disease
phenotype. In family 2, all three mem-
bers with overt EPP have the C683-T
mutation in combination with the trans
IVS348C polymorphism (Figure 1b).
This suggests a pathogenic role of the
IVS348C mutation in reducing FECH
expression levels, as described above
for family 1. Genotyping of the two
Japanese EPP families indicates that at
least in the families examined, the
intronic IVS348C polymorphism in
the non-mutated allele is apparently a
determinant of the EPP phenotype.
However, several researchers indepen-
dently reported patients with overt EPP
who had not inherited the low-expres-
sing allele (Risheg et al., 2003; Wiman
et al., 2003; Whatley et al., 2004),
suggesting that other genetic and/or
acquired factors might play a role in
causing the EPP phenotype in the pres-
ence of a deleterious FECH mutation. In
this context, it is notable that Whatley
et al. (2004) diagnosed three patients
with the IVS348T/T genotype as auto-
somal-recessive EPP, indicating that this
mode of inheritance may explain overt
EPP patients without an IVS348C
allele.
We speculate that the genotypic
frequency of the splice site modulator
IVS48C may affect the penetrance of
the EPP phenotype in affected families
and the prevalence of the disease in
populations. To determine the fre-
quency of IVS48C polymorphism in
the Japanese population, genotyping of
104 control individuals was conducted
by restriction endonuclease digestion
analysis. As shown in Table 1, the
genotypic frequency of IVS348C/C in
the Japanese population was 0.192,
which is over 10 times that of the
individuals from European countries
(Table 1). These striking interracial
differences in the genotypic frequencies
of the IVS348C polymorphism
prompted our hypothesis that the pre-
valence of EPP in the Japanese popula-
tion and the penetrance of the EPP
phenotype in affected Japanese families
would be higher than those in Western
countries. However, the prevalence of
EPP in our country has not been
Table 1. Genotypic and allelic frequencies of the IVS348T/C shift in 104 Japanese controls and in comparison to
Western populations
Genotypic frequency Allelic frequency
Controls T/T C/T C/C T C References
Japanese (n=104) 0.289 0.519 0.192 0.548 0.452 This study
White French (n=350) 0.888 0.095 0.017 0.941 0.061 Gouya et al. (2002)
Caucasian (n=50) ND ND 0 0.92 0.08 Wiman et al. (2003)
Healthy2 (n=83) and control (n=17) 0.93 0.07 0 0.965 0.035 Risheg et al. (2003)
Residents of the UK (n=100) 0.87 0.13 0 0.935 0.065 Whatley et al. (2004)
ND: not determined.
1These figures were calculated from the genotypic frequency, as the original data appear to be miscalculated.
2Controls had non-virally caused liver disease.
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precisely determined thus far, whereas
the worldwide prevalence of EPP has
been reported to be 1:75,000–
1:200,000 (Todd, 1994). Thus, a na-
tionwide survey and genotyping of the
large number of Japanese EPP families
is recommended and would be re-
quired to elucidate the virtual pene-
trance and prevalence of EPP in Japan.
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TO THE EDITOR
Exposure to house dust mite allergens is
an important risk factor for the produc-
tion of specific IgE and is associated
with allergic diseases such as asthma,
rhinitis, and atopic dermatitis (Platts-
Mills and Chapman, 1987). House dust
mite Group 1 allergens, Der f 1 from
Dermatophagoides farinae and Der p 1
from Dermatophagoides pteronyssinus,
are major allergens and belong to the
papain-like cysteine protease family
(Thomas et al., 2002). Their proteolytic
activity has been suggested to be
involved in the pathogenesis of allergies
by facilitating the passage of their own
and other allergens across the epi-
thelium, cleaving and/or interacting
with cell-surface molecules and intrin-
sic protease inhibitors, and modulating
the function of various cells (Comoy
et al., 1998; Shakib et al., 1998; Gough
et al., 1999; Takai et al., 2005a).
Although mite-derived proteolytic ac-
tivities have been reported to disrupt
the bronchial epithelial barrier (Herbert
et al., 1995; Wan et al., 1999), whether
they disrupt the skin barrier, which is
considered a much more rigid barrier
system, has not been investigated.
Here, we test whether the proteolytic
activity of Der f 1 causes a reduction in
the barrier function of the skin in nude
mice using a recombinant Der f 1 (rDer
f 1) with full cysteine protease activity.
We demonstrated that rDer f 1
activated with L-cysteine reduced the
barrier function of the skin in dose- and
time-dependent manners (Figure 1) and
that the reduction was dependent on its
proteolytic activity (Figure 2). All ani-
mal studies have been approved by the
Review Board of Juntendo University.
By the use of nude mice, experimental
procedures were simplified because of
their hairless phenotype, and effects of
T cell-mediated acquired immunity on
the barrier dysfunction could be ig-
nored. The critical permeability func-
tion of the skin is mediated by the
outermost layer of the epidermis, the
stratum corneum (Strid and Strobel,
2005). The barrier function was eval-
uated based on two parameters, transe-
pidermal water loss (TEWL) and the
penetration by riboflavin of the stratum
corneum. TEWL is a parameter for
dryness of the skin, whereas riboflavin
penetration is considered a parameter
of the accessibility of the skin to
environmental allergens and irritants.
On Day 7, TEWL and riboflavin pene-
tration were significantly increased by
administration of 1 or 5 mg/site (Figure
1a) and 5 mg/site (Figure 1b) of activated
rDer f 1, respectively, compared with
the vehicle control. No increases were
observed on Day 3 (Figure 1c and d).
TEWL was greater at the patched site
than water-treated site even in the
vehicle control suggesting that the
vehicle solution containing dilutedAbbreviations: rDer f 1, recombinant Der f 1; TEWL, transepidermal water loss
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